“…[ 5,6 ] In recent years, metal‐N‐heterocyclic carbene (NHC) complexes have shown promise in biomedical applications, including as antimicrobial, anticancer, and antitumor (palladium‐, copper‐, silver‐, gold‐, ruthenium‐, rhodium‐, and platinum‐NHC) agents. [ 7–36 ] The efficacy of a silver‐based drug appears to be linked to its bioavailability [ 13,37 ] which is affected by, for example, its solubility and the presence of biological ligands and halides. The release rate of silver from a prodrug is linked to the ancillary ligand, and as NHCs are strong σ donors, silver‐NHCs can have a slow silver release rate.…”